Locus Cell Co

Locus Cell Co OCF/Debt

The Operating Cash Flow to Debt Ratio of Locus Cell Co (6891.TWO) as of Oct 16, 2026 is -152.71 %. In the previous year, Operating Cash Flow to Debt Ratio was -98.62 % — a change of 54.85% (lower).

OCF/Debt

-152.71 %

YoY

54.85%

Last updated:

Operating Cash Flow to Debt Ratio of Locus Cell Co is 2024 -152.71 % . Operating Cash Flow to Debt Ratio of Locus Cell Co was 2023 -98.62 % . It decreases by 54.85% lower compared to the previous year.

The Locus Cell Co OCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF/Debt
Date
OCF/Debt
Jan 1, 2021
-42.68 TWD
Jan 1, 2022
-47.63 TWD
Jan 1, 2023
-98.62 TWD
Jan 1, 2024
-152.71 TWD
The Locus Cell Co OCF/Debt history
YEAROCF/DebtYoY
-152.71 %+54.85%
-98.62 %+107.07%
-47.63 %+11.60%
-42.68 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Locus Cell Co Stock analysis

What does Locus Cell Co do? Locus Cell Co Ltd is a company based in Taipei, Taiwan, operating within the Health Care sector, specifically in the Life Sciences Tools & Services industry. The company has 32 employees and went public on April 28, 2022. Its primary business involves the entrusted development and manufacturing of cell therapy-related products. Locus Cell Co Ltd utilizes a pilot facility compliant with Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S) good manufacturing practices (GMP). The company provides services including process development and scale-up for cell therapy products, analytical method development and validation, clinical GMP manufacturing for trials, and stability testing. It is anticipated to offer services for various cell therapy applications, such as tissue engineering, CAR-T, induced pluripotent stem cells (iPSCs), and mesenchymal stem cells (MSCs). The company's website is http://www.locus-cell.com/. Locus Cell Co Ltd focuses on contract development and manufacturing organization (CDMO) services for cell therapy products, aiming to support the advancement of innovative therapies through its specialized GMP-compliant facility and technical expertise in cell therapy processes. Locus Cell Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Locus Cell Co stock

Operating Cash Flow to Debt Ratio of Locus Cell Co is -152.71 % in 2024.

Operating Cash Flow to Debt Ratio of Locus Cell Co changed from -98.62 % to -152.71 %, representing a 54.85% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow to Debt Ratio Locus Cell Co since 2006 – with annual values, charts, and detailed analysis.

OCF/Debt measures what percentage of total debt can be covered by annual operating cash flow. Higher ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow to Debt Ratio's Locus Cell Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Locus Cell Co

All Key Metrics — Locus Cell Co